Diabetic retinopathy (DR) is an important cause of avoidable blindness worldwide. Seventy percent of diabetes occurs in low and lower-middle income countries. Clinical practice guidelines for the management of DR have been implemented throughout the world, but mainly in developed nations. However, there is considerable variation between existing guidelines in the recommended frequency of referral, methods for examination and personnel involved in screening and review. This review compares the differences between current available guidelines in the context of the current medical evidence and also addresses the implications for management of DR in countries with limited resources.

**Materials & methods**
A structured search was conducted to identify existing DR guidelines for patients with Type 1 and 2 diabetes. This was performed by searching electronic databases: MEDLINE, CINAHL, PubMed, Web of Science, Scopus and the Cochrane library. The following websites were also searched: WHO, the National Health and Medical Research Council (NHMRC), International Agency for Prevention of Blindness (Vision 2020), International Council of Ophthalmology, NICE, National Screening Committee (NSC), ClinicalTrials.gov, National Guideline Clearing house and Google Scholar. Titles, abstracts and articles were searched for the terms ‘diabetic retinopathy’, ‘screening’ and ‘clinical guidelines’. Guidelines were assessed adapting domain concepts outlined in the Conference of Guideline Standardisation [6] and the Appraisal of Guidelines for Research and Evaluation Instruments [7]. However, the purpose of the review was not to ‘score’ guidelines as such, but rather to compare the content in each with the highest level of evidence.

**Inclusion criteria**
The criteria for inclusion were based on research questions set by the NHMRC multidisciplinary expert panel working group for guideline development. Guidelines included for this review...
were required to meet the following component criteria: included the following key components related to DR: epidemiology, stages of DR, detection and management; provided evidence-based recommendations and developed by an expert panel or an authority commissioned by a national authority.

The authors excluded guidelines that were published in a language other than English, content that has been based upon another published guideline or those from the same authority that have been superseded by updated editions.

**Included guidelines**

The database search revealed 123 references, 18 of which were identified as clinical practice guidelines. A further 14 guidelines were identified through an internet search. In total, 32 guidelines for aspects of DR management were available. For the purposes of this review, the authors have included all guidelines that have addressed all key component criteria. (Table 1). Nine guidelines were excluded from the final list as they did not satisfy all inclusion criteria (Appendix A). Eleven guidelines were published in languages other than English (Appendix B). Thus, of the eligible 21 guidelines, 12 (57%) included all key components; 17 (81%) discussed epidemiology; 17 (81%) discussed stages of retinopathy; 20 (95%) discussed detection of DR; 16 (76%) discussed management and 20 (95%) made evidence-based recommendations. It must be acknowledged that some of the excluded guidelines provided specific information pertaining to certain aspects of DR management (e.g., patients with Type 1 diabetes or frequency of examination). Accordingly, relevant aspects of these excluded guidelines have been compared where appropriate.

Overall, the international guidelines all promote early diagnosis, and substantiate recommendations based on evidence. However, as will be discussed, for certain aspects of DR management, there are large variations between guidelines. Furthermore, many of the recommendations assume access to highest-level treatment infrastructure. Largely, there are several issues in simply implementing these guidelines in an environment where access to healthcare service and infrastructure is limited. This was highlighted by only six guidelines (16%) being published in developing countries. This review appraises the current evidence for management of DR, and comments on the strengths and limitations for adaptation of this evidence in the context of low-resource settings.

**Epidemiology of DR**

The need to estimate the demand for DR services is a critical step in the development of clinical guidelines. Worldwide, the global burden of diabetes is estimated at 346 million people [8]. This is projected to increase to 438 million by the year 2030 (4.4% of the estimated world population). While this escalating trend of diabetes was acknowledged across all the guidelines, many were deficient in documenting county-specific population data that would be pertinent in planning and implementing services to manage DR.

The prevalence of diabetes and DR within respective countries and regions were documented to varying quality by the major guidelines (Table 2). In the guidelines published from Europe, North America, India, Malaysia and Australia, regional prevalence of diabetes was documented. Comparatively, the guidelines from low-resourced areas including Kenya, South Africa and Pacific Islands were deficient in basic population data on diabetes, let alone retinopathy. However, much of the quoted data were based on studies that were at least 5 years old, with limited projections of trends of diabetes in these regions. Guidelines from developed countries generally identified that the majority of diabetes was diagnosed in people aged older than 60 years. This was in contrast to Wild et al. who showed that the majority diagnosed with diabetes in developing nations are at a younger age group (45–64 years of age) [9]. This will clearly have long-term implications for retinopathy progression (longer duration of disease), and impact on morbidity and loss of productivity associated with vision impairment.

The growth of diabetes and DR is a major concern for developing countries. However, this was not necessarily conveyed within the published guidelines. Since the time of publication of most guidelines, several population-based studies have attempted to estimate the burden of DR in low-resourced countries. Current estimates of the prevalence of any DR among people with diabetes in developing regions range from 19% in Bangladesh [10], 17–22% in India [11–13], 30.3% in Cambodia [14], 37% in Iran [15], 43.1% in rural China [16] and 63% in South Africa [17]. Many of these studies have demonstrated comparable rates to what is observed in developed nations such as Australia [18], the UK [19] and the USA [20], which have 29.3, 39 and 50.3% prevalence of DR, respectively, among those diagnosed with diabetes. This observation is contributed in part by the deficiency of robust epidemiological studies conducted in lower-income countries. One source of estimates of DR prevalence in developing regions has originated from Rapid Assessment of Avoidable Blindness surveys that are designed to estimate the prevalence and causes of blindness in people older than 50 years of age [21]. Given that the majority of patients with diabetes in developing regions fall within the 20–64 age group, this may therefore underestimate the true impact of DR [9]. In addition, there is a high proportion of undiagnosed diabetes in developing regions. This ranges from 52% in India [22,23], to 62.8% in rural China, 66% in Cambodia [24], 85% in sub-Saharan Africa, 70% in Ghana and 80% in Tanzania [25]. This compares with 25% in the UK [26], 27% in the USA [27] and 50% in Australia [28]. Accordingly, estimates of projected growth of diabetes in India, sub-Saharan Africa, Asia and the islands, Latin America and the Middle East by the year 2030 are two- to threefold higher than that of established market economies [9]. Several excellent recent reviews have since highlighted the need to incorporate south Asian and Pacific islanders into the high-risk ethnic group category in order to prioritize screening of individuals in these regions [29,30].

**Risk factors for DR**

The principal risk factors for the development and progression of DR were covered well across the international guidelines. All published guidelines acknowledged that the established risk factors for DR were duration of diabetes, glycemic control [31,32],
hypertension [33,34], dyslipidemia [35,36], nephropathy [37,38] and pregnancy [39]. In particular, the importance of diabetes duration, glycemic control and optimization of blood pressure (BP) was consistently covered.

The significance of glycemic control as a major risk factor for DR was emphasized in all guidelines through the acknowledgement of the landmark studies, the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS). The DCCT was a multicenter randomized control study that examined the effect of glycemic control on the frequency of microvascular complications in patients with Type 1 diabetes mellitus (DM) [31]. The investigators randomized 1441

---

<table>
<thead>
<tr>
<th>Publisher</th>
<th>Title</th>
<th>Country</th>
<th>Date of publication (last updated)</th>
<th>Intended audience</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>NHMRC</td>
<td>Guidelines for the Management of Diabetic Retinopathy</td>
<td>Australia</td>
<td>2008</td>
<td>Clinical practitioners</td>
<td>[153]</td>
</tr>
<tr>
<td>Aravind Eye Care System</td>
<td>Guidelines for the Comprehensive Management of Diabetic Retinopathy in India</td>
<td>India</td>
<td>2008</td>
<td>Health services coordinators Primary eye care workers</td>
<td>[154]</td>
</tr>
<tr>
<td>RCO</td>
<td>Guidelines for Diabetic Retinopathy</td>
<td>UK</td>
<td>2005</td>
<td>Ophthalmic specialists</td>
<td>[160]</td>
</tr>
<tr>
<td>AAO</td>
<td>Preferred Practice Pattern</td>
<td>USA</td>
<td>2008 (2011)</td>
<td>Ophthalmic specialists</td>
<td>[161]</td>
</tr>
<tr>
<td>SIGN</td>
<td>Management of Diabetes: A National Clinical Guideline</td>
<td>Scotland</td>
<td>2010</td>
<td>Clinical practitioners</td>
<td>[162]</td>
</tr>
<tr>
<td>WHO</td>
<td>Prevention of Blindness from Diabetes Mellitus</td>
<td>Switzerland</td>
<td>2005</td>
<td>Clinical practitioners Health services staff</td>
<td>[163]</td>
</tr>
<tr>
<td>Ministry of Health Malaysia</td>
<td>Screening of Diabetic Retinopathy</td>
<td>Malaysia</td>
<td>2011</td>
<td>Clinical practitioners</td>
<td>[164]</td>
</tr>
<tr>
<td>Pacific Eye Institute, New Zealand</td>
<td>Diabetes Retinal Screening, Grading and Management Guidelines for Use in Pacific Island Nations</td>
<td>Fiji</td>
<td>2010</td>
<td>Clinical practitioners Health services coordinators Primary eye care workers</td>
<td>[165]</td>
</tr>
<tr>
<td>ISPAD</td>
<td>Microvascular and Macrovascular Complications in: Clinical Practice Consensus Guidelines 2009 Compendium</td>
<td>Australia</td>
<td>2009</td>
<td>Clinical practitioners</td>
<td>[166]</td>
</tr>
</tbody>
</table>

patients with Type 1 DM to receive intensive glycemic control (median HbA1c: 7.3%) compared with conventional levels of control (median HbA1c: 9.1%). The results demonstrated that over a 6.5-year follow-up, intensive glycemic control compared with conventional treatment was associated with reduction in any DR by 76% (95% CI: 62–85) [40], and progression of DR by 54% (95% CI: 39–66) [41]. Similarly, in the UKPDS, the investigators randomized 3867 patients with newly diagnosed Type 2 DM to receive intensive treatment (oral hypoglycemic medication or insulin) or conventional glycemic control (diet control) over a period of 10 years [32]. The results demonstrated that intensive treatment reduced the development of any DR by 25% (95% CI: 7–40). Furthermore, this was associated with a 29% reduction (relative risk: 0.71; 95% CI: 0.53–0.96; p = 0.003) in progression to requirement of laser photocoagulation in the intensive group compared with conventional treatment.

The rationale for tight BP control has similarly been explored in landmark studies. In the UKPDS, 1048 patients with Type 2 DM were randomized to receive intensive BP control of patients with Type 2 DM (target BP; <150/<85 mmHg) versus <180/<105 mmHg, with observation over a period of 9 years. The study demonstrated that intensive control of hypertension was associated with reduction in progression of DR (34 vs 51%; p < 0.05), reduction in moderate vision loss (10 vs 19%; p < 0.05), and reduction in need for photocoagulation (relative risk: 0.65, 95% CI: 0.39–1.06; p = 0.023) [33]. However, there is conflicting evidence regarding whether aggressive treatment of normotensive patients is beneficial in DR. The EUCLID demonstrated over a 2-year follow-up that lisinopril (antihypertensive agent) reduced the progression of any DR by 50% (95% CI: 0.28–0.89; p = 0.02), and progression to proliferative DR (PDR) by 80% (95% CI: 0.04–0.91; p = 0.04) in patients with Type 1 DM with normal BP and renal function [36]. Recently, a 4-year follow-up from the ACCORD Eye study ‘blood pressure’ trial demonstrated that there was no significant difference in the progression of DR with intensive (target systolic BP: <120 mmHg) versus standard BP control (target systolic BP: <140 mmHg) in patients with Type 2 DM [42]. The authors reported no statistically significant difference in any progression of DR (odds ratio: 1.23; 95% CI: 0.84–1.79); or rate of moderate vision loss (hazard ratio: 1.17; 95% CI: 0.96–1.42). Nevertheless, it is clear that optimization of BP in patients with hypertension is a major factor in attenuating the progression of DR.

Guidelines also consistently emphasized the role of early examination in reducing the risk of DR progression. Guidelines from developing regions used data from WESDR and the ETDRS, which demonstrated that after 15 years, retinopathy is noted in almost all people with Type 1 DM and 75% of people with Type 2 DM; 2% become blind and 10% develop severe vision impairment [8,43,44]. The role of puberty as a risk factor for DR among
patients with Type 1 DM was acknowledged by all guidelines except South Africa and Aravind. This was consistent with findings from several studies that demonstrated that physiological changes post puberty accelerated the development of microvascular complications including DR \[44,46\]. Consequently, puberty is now accepted as a risk factor for onset of DR.

The significance of ethnic background upon risk of DR is well established. Many of the guidelines identified high-risk ethnic groups within their population. The American Academy of Ophthalmology (AAO) identified African–Americans and Mexicans as having a greater risk of developing any DR compared with Americans of European descent \[47\]. The NHMRC in Australia estimated that 31% of indigenous people with DM had evidence of retinopathy, compared with 20% in the nonindigenous population. Recent meta-analysis of population-based studies from around the world demonstrated that the age-standardized prevalence of any DR at 49.6% among African–Americans, 34.6% among Hispanic populations, 19.9% in Asians, compared with 45.8% in Caucasians \[38\]. While this was the first meta-analysis to incorporate risk factor data from Asia, the authors acknowledged the deficiency of good quality population studies from the Middle East, Africa and South America. The guidelines for the Pacific Islands, although based on the New Zealand Ministry of Health recommendation, stated that the proportion of any DR among the diabetic population exceeded 50% in some Pacific countries. This is consistent with trends from a recent systematic review that demonstrated that Oceania had the largest DM prevalence (15%) and highest average fasting plasma glucose level of any region in the world \[48\]. The South African and Malaysian guidelines each acknowledged that people of Indian background were at elevated risk of DR compared with the locals (African and Malay, respectively). This was supported by findings from several cross-sectional studies in India that demonstrated up to 25% prevalence of DR among patients with DM \[11,22\]. More recently, the UK Asian Diabetes Study also identified people with south Asian ethnicity as possessing an elevated risk of DR after controlling for other risk factors \[49\]. However, none of the published guidelines mentioned Indians or south Asians as a high-risk ethnic group. The Australian guideline was the only one to offer insight into factors contributing to ethnic differences. They acknowledged the role of westernization and change from traditional diets and lifestyle of indigenous people as a significant contributor to the higher prevalence rate of DM.

### Disease onset & progression & implications for timing of first examination

The necessity to examine all patients with DM for retinopathy at least every 2 years is uniformly accepted by all international guidelines. The recommended timing of first examination is largely consistent between publications and is supported by the published literature (Table 3). In the context of Type 2 DM, there was unanimous concordance among the major international guidelines that all people should be examined using a minimum of dilated fundoscopy and visual acuity measurement by an ophthalmologist, optometrist or suitably trained professional at the time of diagnosis. For patients with Type 2 DM, consensus in the guidelines recommended ophthalmic examination (comprising of fundoscopy and repeated visual acuity measurement) at the time of diagnosis. The rationale for this was supported by the observation that time of onset of Type 2 DM is often difficult to determine \[50\], and that a third of Type 2 DM patients will have some evidence of retinopathy at diagnosis \[44,51\].

For children with Type 1 DM, the majority of guidelines recommend first examination to commence at or soon after puberty (aged 11–12 years). The rationale for delayed screening in children was based primarily from the WESDR, which demonstrated that DR rarely developed in children with Type 1 DM younger than 10 years of age \[43\]. Several follow-up studies concluded that sight-threatening retinopathy (proliferative retinopathy or macular edema) was rare before puberty \[52,53\]. In postpubertal patients with Type 1 DM, guidelines from New Zealand, the Pacific Islands and North America recommended first retinal examination commence after 5 years from the time of diagnosis. This is supported by evidence that showed that the prevalence of DR rapidly increased after 5 years duration of DM \[52\]. More recent prospective studies have demonstrated that after at least 25 years with DM, almost all patients with Type 1 DM developed DR, and between 44 and 50% developed advanced retinopathy \[54,55\]. For patients with Type 1 DM for more than 20 years, this conferred a 15-times greater risk of proliferative DR, and five-times greater risk of diabetic macular edema (DME), compared with those with Type 2 DM for <10 years \[30\]. It is important to note that guidelines were based on studies conducted in Western populations where retinopathy occurred in 8–9% in patients younger than 13 years of age, and 28–34% in those older than 13 years \[56,57\]. Comparatively, recent observations from Tanzania showed 22% of 5–18 year olds with Type 1 DM had evidence of retinopathy at diagnosis. These suggest that emphasis on facilitating examination earlier than 5 years from time of diagnosis for people with Type 1 DM may be required in low-resourced countries \[58\].

It is established that physiologic and metabolic changes associated with pregnancy can accelerate DR \[39,59\]. The recommended timing of examination during pregnancy was stratified into patients with existing DM and those who developed gestational DM (GDM). In the context of patients who develop glucose intolerance during pregnancy (GDM), the AAO and NHMRC stated that DR screening was not routinely required as there was minimal risk for DR in such individuals during pregnancy. Presently, only a single case report has identified vision-threatening retinopathy arising in a patient with GDM \[60\]. While there is insufficient evidence assessing the temporal progression of retinopathy in this group, GDM is associated with elevated risk of long-term DM \[61\]. Accordingly, ophthalmic review at time of diagnosis of GDM may be justified as per the Malaysian guidelines.

For patients with DM diagnosed before pregnancy, the consensus among guidelines recommended a comprehensive eye examination for all pregnant women with DM during the first trimester of pregnancy (Table 4). This was supported by findings from the DCCT that showed greatest risk of DR progression in
the second trimester of pregnancy in patients with Type 1 DM [62]. Most guidelines recommended that women with DM have an ophthalmic examination prior to becoming pregnant, and counseled on the risk of development and progression of DR. Several studies have shown that optimization of glycemic control and BP prior to conception can attenuate the risk of progression of DR [62–64]. For patients with DR detected during pregnancy, there was variation in recommended follow-up schedule between guidelines. This was partly accounted for by a deficiency of recent studies. Evidence suggests that progression of retinopathy is uncommon if absent or mild at the beginning [62]; however, vision-threatening disease can occur [65]. The DCCT also demonstrated that the short-term increased risk in the level of retinopathy in pregnancy could persist up to 12 months postpartum [62,66,67]. Accordingly, close observation of patients with DR during and after pregnancy is warranted.

Assessment of DR: standard classification

The importance of classifying the natural progression of DR is critical for recognition of stages of disease which require treatment. Since the original classification of DR was described in the Airlie House Symposium in 1968, several modified classification systems have developed that have been integrated into the published guidelines [68–73]. The basis of these classification systems has been the understanding of the natural progression of DR gained from the ETDRS. This stratified risk for DR based on observed features of fundus images that were compared with a series of standard stereoscopic slides [74]. The ETDRS levels of retinopathy severity have since been regarded as the ‘gold standard’ for use in clinical and epidemiologic studies [68]. However, the applicability of the ETDRS scoring system in daily clinical practice was restricted due to its multiple levels of severity that are often unnecessary to patient care, complicated grading rules for the different stages and the need for correlation with standard retinal images [69].

Alternate classification systems have been developed by the NSC (UK), Scottish Diabetic Retinopathy Grading Scheme and Royal College of Ophthalmologists (RCO; UK). The subtle differences between these and the international classification existed in the description of nonproliferative diabetic retinopathy (NPDR). These were compared in a simple table in the RCO guideline (Appendix C). The simplest grading system was developed by the RCO, which stratified DR into ‘none’, ‘low-risk’, ‘high-risk’ and ‘PDR’. However, treatment recommendations by the RCO referred to studies using the ETDRS or international classifications.

The International Clinical Diabetic Retinopathy and Diabetic Macular Oedema Severity Scale, developed in 2001, has since been adopted for guidelines developed in North America, Australia,

### Table 3. Comparison of recommended timing of first retinal examination.

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Type 1 DM</th>
<th>Type 2 DM</th>
<th>Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>NICE</td>
<td>Adults: time of diagnosis; children: commence from age 12</td>
<td>Time of diagnosis</td>
<td>Before and during pregnancy first trimester</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>If DR detected: 16–20 weeks and 6 months postpartum</td>
</tr>
<tr>
<td>Kenya</td>
<td>From initial visit</td>
<td>Time of diagnosis</td>
<td>During first trimester</td>
</tr>
<tr>
<td>RCO</td>
<td>Commence above 12 years of age</td>
<td>Time of diagnosis</td>
<td>Before pregnancy and in each trimester</td>
</tr>
<tr>
<td>WHO</td>
<td>Time of diagnosis</td>
<td>Time of diagnosis</td>
<td>Not stipulated</td>
</tr>
<tr>
<td>Aravind</td>
<td>Not stipulated</td>
<td>Time of diagnosis</td>
<td>Before pregnancy and during first trimester</td>
</tr>
<tr>
<td>NHMRC</td>
<td>Prepubertal diabetes onset: examine at puberty; postpubertal diabetes onset: examine at time of diagnosis</td>
<td>Time of diagnosis</td>
<td>During first trimester</td>
</tr>
<tr>
<td>Canada</td>
<td>5 years after diagnosis for patients aged ≥15 years</td>
<td>Time of diagnosis</td>
<td>Before pregnancy and during first trimester</td>
</tr>
<tr>
<td>Pacific Eye Institute</td>
<td>Adults: after 5 years from diagnosis; children: after 5 years from diagnosis, or at puberty (whichever is earlier)</td>
<td>Time of diagnosis</td>
<td>Early in first trimester</td>
</tr>
<tr>
<td>SIGN</td>
<td>Commence from 12 years of age</td>
<td>Time of diagnosis</td>
<td>Examine before pregnancy and during each trimester</td>
</tr>
<tr>
<td>AAO</td>
<td>3–5 years after diagnosis</td>
<td>Time of diagnosis</td>
<td>Examine before pregnancy and early in first trimester</td>
</tr>
<tr>
<td>Malaysia</td>
<td>Children: from aged years 11 (if 2 years duration) or from aged 9 (if 5 years duration)</td>
<td>Time of diagnosis; children with type 2 DM: time of diagnosis</td>
<td>Examine before pregnancy and during first trimester</td>
</tr>
</tbody>
</table>

Asia, Africa and Asia–Pacific region. The new classification incorporated evidence on disease progression from the ETDRS, and stratified DR into five levels of severity based on observed retinal changes [69]. The main distinctions offered in the international severity scale are that the levels of severity are each relevant to the clinical management decisions for the patient. This offered a simpler method to assess risk of progression of DR, and facilitated communication between ophthalmologists and primary healthcare providers. Accordingly, the international classification system has been endorsed by most international authorities including the WHO as a standard system for guiding evidence-based practice. While the international classification system has not replaced the ETDRS, it has been demonstrated as a useful guide for population screening, and facilitating timely treatment [15,75].

### Table 4. Frequency of examination and referral to ophthalmologist.

<table>
<thead>
<tr>
<th>Guideline</th>
<th>No retinopathy</th>
<th>Mild NPDR</th>
<th>Moderate NPDR</th>
<th>Severe NPDR</th>
<th>PDR</th>
<th>CSME</th>
<th>Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>NICE</td>
<td>Annual review</td>
<td>Annual review</td>
<td>3–6 months</td>
<td>Within 4 weeks</td>
<td>Within 1 week</td>
<td>Within 4 weeks</td>
<td>16–20 weeks and 6 months postpartum</td>
</tr>
<tr>
<td>South Africa</td>
<td>Annual review</td>
<td>12 months</td>
<td>6 months</td>
<td>Urgently for pan-retinal photo coagulation</td>
<td>Urgently for pan-retinal photocoagulation</td>
<td>Urgent referral to ophthalmologist</td>
<td>Not stipulated</td>
</tr>
<tr>
<td>RCO</td>
<td>Annual review</td>
<td>Annual review</td>
<td>Within 4 months</td>
<td>Within 4 months</td>
<td>Within 2 weeks</td>
<td>Within 2 weeks</td>
<td>In each trimester, and 3–9 months postpartum</td>
</tr>
<tr>
<td>WHO</td>
<td>Annual review</td>
<td>6–12 months</td>
<td>6–12 months</td>
<td>2–4 months</td>
<td>2–4 months</td>
<td>2–4 months</td>
<td>Not stipulated</td>
</tr>
<tr>
<td>NHMRC</td>
<td>2 yearly annual review for high-risk patients</td>
<td>Annual review</td>
<td>3–6 months</td>
<td>Within 3–6 months</td>
<td>Within 4 weeks</td>
<td>Within 4 weeks</td>
<td>If DR found, need close follow-up throughout pregnancy</td>
</tr>
<tr>
<td>Pacific Eye Institute</td>
<td>12 months</td>
<td>6 months</td>
<td>Within 6 weeks</td>
<td>Within 4 weeks</td>
<td>Within 1 week</td>
<td>Stable: 12 months</td>
<td>If DR detected at least 2-monthly intervals</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Severe: within 1 week</td>
<td></td>
</tr>
<tr>
<td>SIGN</td>
<td>2 yearly</td>
<td>Annual review</td>
<td>Within 18 weeks</td>
<td>Within 12 weeks</td>
<td>Urgently for laser treatment</td>
<td>During each trimester</td>
<td></td>
</tr>
<tr>
<td>AAO</td>
<td>Annual review</td>
<td>6–12 months</td>
<td>6–12 months</td>
<td>2–4 months</td>
<td>2–4 months</td>
<td>Presence of CSME requires minimum 2–4 monthly review</td>
<td>If nil or minimal DR: 3–12-monthly follow-up</td>
</tr>
<tr>
<td>Malaysia</td>
<td>12–24 months</td>
<td>9–12 months</td>
<td>6 months</td>
<td>Within 4 weeks</td>
<td>Within 1 week</td>
<td>Any maculopathy: within 4 weeks</td>
<td>Nil to moderate DR: 3-monthly Moderate or worse: urgent referral</td>
</tr>
</tbody>
</table>

AAO: American Academy of Ophthalmology; CSME: Clinically significant macular edema; DR: Diabetic retinopathy; NHMRC: National Health and Medical Research Council; NPDR: Nonproliferative DR; PDR: Proliferative DR; RCO: Royal College of Ophthalmologists.
Assessment of DR: frequency of examination
While there was general consensus among published guidelines regarding the timing of the initial examination, there were differences between follow-up examination schedules (Table 4).

No retinopathy
For patients without evidence of retinopathy, guidelines from South Africa, NICE, RCO, AAO and the Pacific Islands recommended annual follow-up. The AAO referenced the WESDR that demonstrated that at 1 year, 5%–10% of patients with a normal retinal examination at baseline had progressed to some evidence of DR. The 4-year incidence of any DR was 59% in patients with Type 1 DM and 34% in Type 2 patients [43]. The NHMRC was the only publication that identified and recommended that patients at elevated risk (longer duration, poor glycemic control, hypertension, hyperlipidemia or from an indigenous background) required at minimum annual review. The necessity for greater vigilance particularly for the indigenous population is supported by recent evidence which demonstrated that indigenous people in Australia developed vision-threatening disease (particularly clinically significant macular edema [CSME]) from a normal baseline at an earlier stage than nonindigenous populations [76, 77]. Extension of the examination schedule to 2-yearly intervals for most patients was recommended by the NHMRC, Scottish Intercollegiate Guidelines Network (SIGN), New Zealand and Malaysia. Evidence-based justification for the timing between examinations were based on findings from studies subsequent to WESDR, including the UKPDS, showed that 22% with a normal baseline examination developed DR after 6 years [78]. Comparable data showing half the incidence in the WESDR was also demonstrated in the Blue Mountains Eye Study [79], Melbourne Visual Impairment Project [80] and UKPDS [78]. In the context of these findings, The Liverpool Diabetic Eye Study concluded that the rate of progression to sight-threatening DR among people with normal baseline was so low that a conservative screening period of 2–3 years could be reliably adopted [81]. A more recent meta-analysis by Wong et al. demonstrated that for patients with nil retinopathy at baseline, the progression to PDR after 4 years was 2.6% in studies published between 1986 and 2008, compared with 6.3% in prior studies [82]. The authors concluded that this difference may be accounted for by optimization of risk-factor control among patients with DM. This was supported by a meta-analysis of health economic evidence that demonstrated that for patients with good glycemic control and no background retinopathy, biennial or triennial screening was more cost effective than annual examination [83]. Despite this evidence, guidelines developed for low-resource areas (South Africa, Kenya and the Pacific Islands) all recommend annual screening intervals. The rationale for annual screening in these areas can perhaps be contextualized by the differences in disease prevalence and ‘high-risk’ ethnic groups. Furthermore, it must be considered that findings from the Liverpool Diabetic Eye Study related to the end point of sight-threatening disease. The extension of the screening interval beyond 2 years failed to consider the effect that lower levels of DR severity impart on patient visual morbidity, and the additional benefits associated with clinician–patient continuity of care to opportunistically detect other associated eye conditions more frequent in DM (e.g. cataract and glaucoma) [84, 85]. Thus, at present, current evidence indicates that patients without an elevated risk of DR can safely be reviewed at 2-yearly intervals.

Mild-to-moderate NPDR without macular edema
The recommended frequency of examination for patients with mild-to-moderate nonproliferative DR without macular edema varied between published guidelines. While all guidelines recommended annual examination, the AAO, WHO, Pacific Islands and Malaysia suggested patients could be reviewed more frequently, at 6–12 monthly intervals. The AAO referenced the WESDR that demonstrated that 16% of Type 1 DM patients with mild retinopathy (hard exudates and microaneurysms only at baseline examination) progressed to proliferative disease after 4 years [52]. For Type 2 DM, 34%–47% experienced worsening of retinopathy over a similar period [86]. More conservative estimates of progression were demonstrated in the 6-year follow-up data from the UKPDS. This showed that 29% of patients with retinopathy at baseline progressed by at least two ETDRS levels of severity. Eighteen percent with mild-to-moderate NPDR at baseline progressed to need photocoagulation at 6 years [78]. Recently, a 4-year follow-up of patients with Type 2 DM demonstrated an escalation in incidence of DR from 5.8 to 20.3% between 1- and 2-year follow-ups [87]. This strongly supports the current recommendations for at least annual review in these patients.

Severe NPDR
In the context of patients with severe nonproliferative DR, all guidelines addressed the necessity for more frequent review of patients. Prompt referral within 4 weeks was advocated by NICE, New Zealand/Pacific Islands, Malaysian and South African guidelines. Comparatively, the WHO, AAO, NHMRC, RCO and SIGN while acknowledging the importance of early examination by an ophthalmologist, offered a range between 2 and 6 months. The rationale for at least four monthly examinations was derived from the ETDRS protocol, which reviewed patients with mild-to-severe NPDR. This demonstrated that 45% of patients with severe NPDR developed PDR within 1 year, increasing to 71% after 5 years [3]. Subsequent analyses from the ETDRS demonstrated that early referral for retinal photocoagulation for patients with severe NPDR reduced the risk of severe vision loss or need for vitrectomy by 50%, compared with deferring until high-risk PDR developed [88]. The difficulty in determining an ‘optimal’ period of review for severe NPDR rests with limitations in the literature. As highlighted by Wong et al., many of the ‘landmark’ studies had larger proportions of more advanced DR at baseline [82]. In addition, the advances and access to modern treatment modalities would therefore pose challenges to designing a new prospective study. Thus, given the evidence that suggests the propensity for severe NPDR to progress rapidly, current evidence supports a maximum of 4-monthly intervals.
Criteria for urgent referral to an ophthalmologist

The necessity to expedite ophthalmic review for patients with vision-threatening retinopathy was consistently established across the guidelines reviewed. Fundamentally, ‘vision-threatening’ retinopathy was uniformly accepted and defined as encompassing the presence of severe retinopathy (severe NPDR and proliferative DR) and DME. Further consensus was achieved across guidelines that any sudden severe vision loss, or symptoms of retinal detachment, required same-day referral to an ophthalmologist. Overall, all guidelines based their recommendations based on observations from the sentinel studies, the DRS [90] and ETDRS [90] in which photocoagulation was referred as soon as high-risk PDR was detected. These studies demonstrated significant reduction in the risk of severe vision loss among patients with advanced retinopathy with timely retinal photocoagulation. The NICE defined three levels of ‘urgency’: emergency (same day); within 1 week and within 4 weeks. Patients with any form of maculopathy or severe NPDR required review within 4 weeks. The presence of proliferative retinopathy (anywhere), preretinal or vitreous hemorrhage required review within 1 week. This model was incorporated into both the Australian and Malaysian guidelines. Similarly, the AAO, SIGN, WHO and South African guidelines all recommended ophthalmic review and treatment to be performed expeditiously for patients with PDR and macular edema. However, they failed to clearly define an ‘urgent’ time frame.

Assessment of DR: detection of DR

The recommended modality for screening for DR varied considerably across the published guidelines (Table 5). While there is no doubt that the advent of digital retinal photography has facilitated greater coverage of retinal photography for the purposes of population screening, there was considerable variation regarding the accepted criteria for the use of digital imaging in DR screening. While different studies have had variations in criteria for reference standards, NICE stipulated that an acceptable DR screening tool with a minimum of 80% sensitivity, 95% specificity and technical failure rate of 5% [91]. This contrasted with the NHMRC that set the minimum sensitivity for a screening test as 60%, with the requisite that repeated examinations would detect any retinopathy missed at earlier examination [92]. The current ‘gold standard’ ETDRS protocol of seven standard (30°) field 35-mm stereoscopic mydriatic color fundus photographs was recommended by the SIGN and Canadian guidelines. Alternative digital fundus imaging protocols capturing two or three fields were recommended by NICE, New Zealand and the WHO. Systematic review of evidence suggests that mydriatic photography is the most effective screening strategy, with high sensitivity (87–97%) and specificity (83–92%) for detection of sight-threatening DR [93]. Joannou et al. showed that single-field 60° mydriatic photography had a sensitivity and specificity of 93 and 89% for detection of any retinopathy, and 100 and 75%, respectively for severe DR [94]. Importantly, Maberly et al. showed that mydriatic 45° fundus images were shown to have a high sensitivity (93.3%), specificity (96.8%) and positive-predictive value (67.8%) for detecting PDR or CSME [95]. While multiple-field mydriatic photography demonstrated greater sensitivity compared with single-field photography, several limitations were noted in the guidelines [96-98]. These included the time taken to obtain and interpret the photographs, constraints upon availability and training for ophthalmic workforce, the need for dilating drops and its associated issues related to patient compliance [99].

The limitations of mydriatic photography prompted the NHMRC, Pacific Islands and Malaysian guidelines to propose the use of non-mydriatic retinal cameras as a suitable alternative for DR screening. Their recommendations were supported by evidence that showed that high-quality single-field, 45° non-mydriatic photography demonstrated sensitivity (71–84%) and specificity (93–98%) for the detection of referable retinopathy, including proliferative DR and maculopathy [100-103]. A growing body of evidence has endorsed non-mydriatic photography as a practical method for population screening, particularly in rural and remote areas where fundamentally, the decision to refer or not is required [104]. Harper et al. showed that single 45° field non-mydriatic images using the Canon CR45 camera could be reliably performed with a 5% technical failure rate, in rural areas by trained, nonophthalmic technicians, with off-site central grading of images [105]. Diamond et al. using the same camera further demonstrated in a rural setting, that single-field non-mydriatic imaging for DR screening was able to capture equivalent ‘adequate’ quality images compared with mydriatic photographs in order to establish presence of retinopathy and need for referral [109]. Importantly, in a systematic review, Jones and Edwards concluded that the use of digital photography, with the use of telemedicine for off-site grading, achieved greater cost-effectiveness than conventional ophthalmoscopy by a traveling ophthalmologist [83].

The limitations of non-mydriatic photography are noted in the literature. In a sample of 3611 patients, Scanlon et al. identified a technical failure rate of satisfactory images using non-mydriatic photography of 19.7%, with full assessment of both eyes achieved in only 48% of patients [106]. However, their study acknowledged that the Sony digital camera used for the study achieved a resolution well below the minimum recommended threshold by the UK NSC. Significant advances in camera resolution have occurred since Pugh et al. showed lower sensitivity of non-mydriatic photography using a Canon CR3 camera compared with mydriatic images in detecting more severe DR [107]. Comparative studies of non-mydriatic to mydriatic retinal photography have widely reported that single-field, nonstereoscopic retinal photographs taken with mydriasis provides superior quality images for the diagnosis of DR [105,106], and reduces the number of patients referred due to ungradable photographs [98]. Furthermore, Bursell et al. noted that in the presence of only a few exudates, distinguishing CSME was limited with nonstereoscopic views through undilated pupils [108]. The image quality was further reduced by the presence of other ocular pathology such as lens opacity [109]. While Aplet et al. demonstrated that sensitivity of non-mydriatic photography was improved to 90% by capturing three 45° retinal fields [100], the use of multiple fields had a small improvement in the positive-predictive value.
Thus, consistent themes that emerged from such studies were the limitations on available technology at the time, and the effect of pupil size.

Specifications of available technology must therefore be considered in evaluating the quality of retinal imaging reported in studies. The popularity of digital photography emerged through the observation of costs and time required for processing, developing and shipping original 35-mm film images for interpretation [110]. In order to comply with ‘gold standard’ ETDRS protocol of seven-field stereoscopic, 35-mm color film protocol, achieving a 2400 × 2000 pixel resolution equated to almost half a gigabyte per patient per visit. With the evolution of high-resolution digital cameras, there is a clear necessity for images to be compressed in order to facilitate archiving and transmission across computer networks [111]. Presently, the United Kingdom NSC recommends high-quality image compression (1:12 rather than 1:20), and a minimum resolution of 20 pixels per degree of retinal imaging [112]. Basu et al. concluded from their evaluation of 290 single-field images taken through a non-mydriatic Canon CR6, 45° field fundus camera that image compression ratios between 1:20 and 1:12 (equating to a file size of 66–107 kilobytes) was the threshold for gradable image quality [113]. Advances in non-mydriatic technology have clearly improved the diagnostic validity of this modality. In 2009, Vujosevic et al. conducted a well-designed masked prospective case series comparing single- and three-field non-mydriatic photography to ETDRS protocol using the Nidek 45° non-mydriatic camera (1392 × 1040 resolution). The authors demonstrated that sensitivity and specificity for referable retinopathy was 71 and 96%, respectively [114]. The sensitivity improved to 82% with three-field non-mydriatic 45° images. Importantly, the study concluded that the resolution offered by a single 45° central field was adequate to determine presence of DR and DME.

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Recommended screening modality</th>
<th>Personnel performing visual acuity and retinal examination</th>
</tr>
</thead>
<tbody>
<tr>
<td>NICE</td>
<td>Retinal photography (mydriatic, 45°) or slit-lamp indirect ophthalmoscopy</td>
<td>Mydriatic photograph evaluated by trained personnel; slit-lamp examination by ophthalmologist or optometrist</td>
</tr>
<tr>
<td>South Africa</td>
<td>Dilated ophthalmoscopy</td>
<td>Ophthalmic medical officer, trained ophthalmic nurse or optometrist</td>
</tr>
<tr>
<td>Kenya</td>
<td>Dilated fundoscopy</td>
<td>Did not stipulate</td>
</tr>
<tr>
<td>RCO</td>
<td>Dilated digital retinal photography</td>
<td>Primary care physicians, optometrists or ophthalmologists</td>
</tr>
<tr>
<td>WHO</td>
<td>Dilated retinal photography (three-field images at a reading centre or two-field images against a photographic standard) or slit-lamp biomicroscopy (dilated) with a lens or dilated fundoscopy including stereoscopic examination of the posterior pole</td>
<td>Trained photographer, optometrists and ophthalmologists</td>
</tr>
<tr>
<td>Aravind</td>
<td>Wide-angle fundus photography</td>
<td>Trained ophthalmic technician (for fundus photography), physicians, diabetologists and ophthalmologists</td>
</tr>
<tr>
<td>NHMRC</td>
<td>Dilated ophthalmoscopy or slit-lamp biomicroscopy (dilated) with a lens or photography (non-mydriatic adequate) if dilated exam not possible</td>
<td>Ophthalmologists, optometrists and other trained medical examiners</td>
</tr>
<tr>
<td>Canada</td>
<td>Seven-standard field stereoscopic colour fundus photography or dilated direct ophthalmoscopy or dilated indirect slit-lamp fundoscopy</td>
<td>Fundus photography interpreted by trained reader</td>
</tr>
<tr>
<td>New Zealand</td>
<td>Dilated retinal photography (2 × 45° fields-macular and nasal) or slit-lamp biomicroscopy</td>
<td>Trained screener and grader (nurses, allied health, mid-level health professionals)</td>
</tr>
<tr>
<td>Pacific Eye Institute</td>
<td>Non-mydriatic digital retinal photography (single 45° field) or slit-lamp indirect ophthalmoscopy through dilated pupils</td>
<td>Trained screener and grader (nurses, allied health, mid-level health professionals)</td>
</tr>
<tr>
<td>SIGN</td>
<td>Retinal photography (seven-field stereoscopic) or slit-lamp biomicroscopy (dilated) one-field 45–50° can be used for screening</td>
<td>Ophthalmologists</td>
</tr>
<tr>
<td>AAO</td>
<td>Slit-lamp biomicroscopy (dilated) with a lens or dilated fundoscopy including stereoscopic examination of the posterior pole</td>
<td>Ophthalmologists; trained individuals under ophthalmologist supervision</td>
</tr>
<tr>
<td>Malaysia</td>
<td>Non-mydriatic retinal imaging (angle not specified) or dilated ophthalmoscopy</td>
<td>Screening and grading by trained doctors, optometrists, assistant medical officers and nurses</td>
</tr>
</tbody>
</table>

Dilated ophthalmoscopy or dilated fundus examination using an indirect lens on a slit-lamp is the preferred practice in the NHMRC, South Africa and Kenyan guidelines. The remaining guidelines recommended that clinical examination was an appropriate method for screening in the absence of photographic facilities or poor quality images. However, evidence suggests significant variability of direct and indirect ophthalmoscopy, even among experienced hands in the ability to detect retinopathy [115].

The Liverpool Diabetic Eye Study demonstrated that direct ophthalmoscopy with mydriasis, even if performed by an experienced ophthalmologist, had inferior sensitivity (65 vs 89%), and specificity for detection of sight-threatening eye disease (86 vs 97%) compared with three-field 45° nonstereoscopic mydriatic photography [116]. The systematic review conducted by Hutchinson et al. demonstrated that the use of direct ophthalmoscopy through dilated pupils in screening for DR was associated with variations in sensitivity (45–98%) and specificity (62–100%) [93]. The validity of direct ophthalmoscopy was further reduced in the hands of less-experienced medical officers [93].

Given this evidence, slit-lamp biomicroscopy performed using an appropriate lens (78 or 90 dioptre) remained an important modality in screening for DR. The necessity for slit-lamp examination has been partly attributed to the influence of ungradable photography. The utility of slit-lamp biomicroscopy was demonstrated by Scanlon et al. who showed that in comparison with seven-field stereoscopic retinal photography, dilated slit-lamp biomicroscopy performed by an ophthalmologist had a sensitivity of 87.4% (95% CI: 83.5–91.5), and specificity of 94.9% (95% CI: 91.5–98.3%) in identifying referable DR (k = 0.80) [106]. The use of slit-lamp biomicroscopy has since been adopted as the ‘reference’ standard in several recent studies comparing modalities of retinal photography for DR as it is much less susceptible to media-opacity related failure [117,118]. While the slit-lamp has advantages of availability and affordability compared with photography, the disadvantages of its routine use in a low-resourced setting included availability of trained ophthalmic staff and need for pupil dilatation.

Current evidence suggests single-field non-mydriatic photography using trained readers is an adequate modality for detecting referable DR, but not a substitute for comprehensive ophthalmic examination when needed. Compared with ophthalmoscopy, single-field photography can offer screening to a greater population. While mydriasis improves the sensitivity, it is restricted by practical limitations. As such, current evidence concurs with the recommendation for the Health Technology Board of Scotland that non-mydriatic one-field photography be used as a first stage, with mydriatic photography used for failures of non-mydriatic photography and examination [71].

**Assessment of DR: Who can examine?**

The availability of sufficient numbers of ophthalmologists to meet the growing demands around the world, particularly in developing regions, has emerged as a major barrier to delivery of timely ophthalmic care. Recent evidence suggests the problem is masked by inequities in distribution of the health workforce, whereby poor working and living conditions and greater income-earning capacity in urban areas means that medical staff are often reluctant to relocate to work in remote areas, and less willing to work in the government health system [119,120]. In order to implement sustainable guidelines, an approach that has been proposed was to ‘task-shift’ to increase reliance on community level and nonophthalmic workers in the process of DR screening [121]. Consensus was achieved among the guidelines that in addition to ophthalmologists, screening could be reliably performed by adequately trained doctors, retinal photographers and optometrists (Table 5). This was particularly emphasized in guidelines from developing regions including India and South Africa where the issue of adequate healthcare personnel has demanded innovative methods of delivering care. The SIGN and AAO guidelines, while recommending that ophthalmologists perform most of the examinations and surgery, acknowledged that ‘trained individuals’ could be involved in the screening process in order to improve access to care. Several studies comparing accuracy of other health professionals in detection and grading DR have been covered well in the literature.

The sensitivity of detecting vision-threatening retinopathy using direct ophthalmoscopy ranged from 41 to 87% among general practitioners [122,123]; 74–100% by optometrists/opticians [124,125] and 14–55% by nurses [107,126]. Buxton et al. compared the sensitivity of detecting vision-threatening retinopathy by hospital physicians and general practitioners in 3318 patients with DR using direct ophthalmoscopy in the UK [122]. General practitioners demonstrated a sensitivity and specificity of 41 and 89%; compared with 67 and 96%, respectively, for hospital physicians. Recently, Gill et al. evaluated the ability of 11 general practitioners to assess for referable DR in 28 patients using a non-mydriatic panoptic ophthalmoscope [123]. The authors compared findings with a series of reference standard retinal diagrams. The results demonstrated a sensitivity of 87% with specificity of 57% for detecting referable DR. Despite these findings, a survey of screening practices by Australian family physicians found only 26% routinely examined their patients with DM for DR. The low rate for ophthalmoscopy was largely accounted for by the deficiency in confidence in detecting changes as reported by 84% of doctors surveyed [127]. Importantly, in the study by Gill et al., prior to examination general practitioners were required to participate in a 4-h tutorial program conducted by a retinal specialist. These findings were consistent with further studies that have demonstrated that the level of knowledge, and clinical skills for detection of DR increased after appropriate and standardized training [128,129].

Several studies demonstrated that optometrists had a high sensitivity for the detection of retinopathy. Kleinstein et al., assessing the accuracy of optometrists using direct ophthalmoscopy in the UK, showed a sensitivity of 74% and specificity of 84% for the presence of DR [124]. Furthermore, the accuracy for diagnosis of retinopathy severity was comparable with general ophthalmologists. Importantly, Burnett et al., in a sample of patients referred from general practices in north London (UK), demonstrated that optometrists were able to assess referable DR with 100%
sensitivity and 94% specificity [125]. In addition, Schmid et al. conducted a comprehensive study of optometrist DR screening practices in northern Australia [130]. They demonstrated a combined approach integrating education of optometrists yielded an agreement of 79% with retinal specialists for appropriately identifying patients requiring specialist-level care.

The utilization of nurses and physician assistants for DR screening has also been explored with varying results. Pugh et al. demonstrated that dilated ophthalmoscopy conducted by trained physician assistants yielded a sensitivity of only 14%, with a specificity of 99%, for assessment of different severity levels of DR in 250 patients compared with the ‘gold standard’ ETDRS [107]. Furthermore, in a community-based setting, Forrest et al. showed that while the accuracy of nurses (sensitivity 50% and specificity 99%) was comparable with diabetologists for the detection of DR using dilated ophthalmoscopy, the ability to detect serious retinopathy was lower by nurses [126].

Due to the variable accuracy of non-ophthalmic personnel to detect DR using ophthalmoscopy, evaluation of clinicians to read retinal images has also been evaluated. Farley et al. evaluated and assessed the accuracy of general practitioners (family physicians) compared with ophthalmologists to grade and appropriately refer retinal images taken using a single-field 45° non-mydriatic retinal camera, of 1040 predominantly Hispanic-background patients attending a general medical clinic. The authors concluded as a primary end point that general practitioners failed to refer only 10.2% of cases which ophthalmologists would have considered necessary [133]. Furthermore, the use of trained graders examining non-mydriatic images for detecting sight-threatening and referable DR has demonstrated a sensitivity of 85–97% and specificity of 80–96% [107,132]. In Spain, Andonegui et al. compared the accuracy of primary care physicians to ophthalmologist in reviewing five-field non-mydriatic photographs in a randomized sample of 200 patients, half with DR [133]. Primary care physicians received online clinical education prior to reviewing the images. The study showed agreement between physicians and ophthalmologists of between 80 and 95%. However, the study failed to assess accuracy in DR severity, which would be important for guiding referral. Nevertheless, a growing body of evidence suggests that dilated examination and reliable interpretation of non-mydriatic retinal photography can be performed by trained personnel to meet screening sensitivity criteria.

**Treatment of DR: laser photocoagulation & vitrectomy**

The indications and timing for photocoagulation and vitrectomy achieved consensus across all guidelines. Laser photocoagulation was consistently observed as the standard practice for treating DR. The NHMRC, AAO, WHO, SIGN, International Society for Pediatric and Adolescent Diabetes and RCO all specified the timing and type of photocoagulation in accordance with the strength of evidence from ETDRS [134] and DRS [32]. Laser photocoagulation was indicated in patients with Type 1 and Type 2 DM with new vessels elsewhere in the presence of vitreous hemorrhage, or with new vessels on the optic disc with or without vitreous hemorrhage. Patients with severe or very-severe NPDR were to be considered for pan-retinal photocoagulation. Furthermore, all guidelines recommended modified ETDRS grid laser photocoagulation in the setting of clinically significant macular edema when macular ischemia is absent. Guidelines also acknowledged the possible adverse effects of laser by suggesting that evaluation of risk and benefits was required when considering photocoagulation for less severe retinopathy. The RCO, Pacific Island, South African, Kenyan and Aravind guidelines did not specify the type of laser used for clinical severity of retinopathy. However, these guidelines were designed principally to guide screening and referral practice to an ophthalmologist for patients with any vision-threatening retinopathy.

Similarly, there was consensus regarding the timing of vitrectomy. The indications and rationale for vitrectomy were derived from the sentinel findings from the Diabetic Retinopathy Vitrectomy Study that demonstrated statistically significant recovery of visual acuity in patients with Type 1 DM [135]. Vitrectomy was indicated across all guidelines recommending vitrectomy in the setting of advanced DR including severe PDR with nonresolving vitreous hemorrhage or fibrosis, retinal detachment or areas of retinal traction that threatened the macula. While the rationale for vitrectomy has changed little since the Diabetic Retinopathy Vitrectomy Study, thresholds for performing surgery have lowered due to the advances in surgical methods and instrumentation [136,137]. The NHMRC was the only guideline to incorporate more recent evidence supporting the consideration of vitrectomy in the management of persistent diffuse macular edema [138,139].

**Emerging ophthalmic treatments**

The recommendations made in the majority of the guidelines were designed to facilitate timely diagnosis and treatment. The content of the guidelines were generally tailored to planning services in their respective regions with prioritization given to meeting the demands in the context of available resources. As such, the only AAO, NHMRC, RCO, SIGN and Malaysian guidelines discussed the role of emerging ophthalmic treatments. While several excellent reviews have discussed the role of medical and ancillary therapies for DR [4,29,140], intracocular steroids and anti-VEGF agents have consistently generated interest as having the greatest potential in treatment of diabetic macular edema and proliferative disease.

VEGF has long been considered an important mediator of neovascularization, and retinal vascular permeability, and therefore a likely therapeutic target for the treatment of proliferative DR and macular edema. Randomized clinical trials have demonstrated that the suppression of VEGF is particularly beneficial in the context of vision-threatening macular edema. Presently, three anti-VEGF medications are available for use: pegaptanib, ranibizumab and bevacizumab.

Bevacizumab is a full length humanized anti-VEGF antibody that inhibits all forms of VEGF-A. Two-year results from the prospective BOLT study suggests that intravitreal bevacizumab is beneficial in reducing DME. The study has demonstrated that among 80 patients with DME, intravitreal bevacizumab was associated with a significant gain of visual acuity, and greater
improvement reduction of central macular thickness letters compared with patients assigned to macular laser treatment alone [141]. Similarly, ranibizumab is a recombinant antibody fragment derived from humanized anti-VEGF antibody that inhibits all isoforms of VEGF-A. The preliminary RESOLVE study demonstrated that intravitreal ranibizumab monotherapy delivered as three consecutive monthly injections (plus ‘as necessary’ injections thereafter) compared with placebo improved visual acuity by an average of ten letters on a Snellen chart at 12 months in 151 patients with diabetic macular edema. This corresponded with a significant reduction in central retinal thickness [142].

Several subsequent randomized control studies have explored the clinical effect of ranibizumab in combination with laser treatment. In the READ-2 study, 126 patients with DME were randomized to receive ranibizumab monotherapy (at baseline, 1, 3 and 5 months), or laser monotherapy (at baseline and 3 months), or combination (at baseline and 3 months). While all treatment groups recorded mean improvement in visual acuity, the greatest gain was recorded in the ranibizumab monotherapy group at 6 months. Importantly, this was preserved at 2-year follow-up [143].

The diabetic retinopathy clinical research network (DRCR.net) randomized 854 eyes with DME to receive either ranibizumab with prompt laser (within 3–10 days of injection), ranibizumab with deferred laser (greater than 24 weeks after injection), triamcinolone plus prompt laser or sham injection plus prompt laser. At 2-year follow-up, greatest improvement in visual acuity from baseline was observed in patients who received intravitreal ranibizumab and deferred laser. When compared with laser plus sham injection, the ranibizumab group were less likely to have marked vision loss compared with laser alone, and sustained an average gain of one-line vision at 2-year follow-up [144,145]. Furthermore, patients in the triamcinolone group were noted to have a mean decrease in visual acuity and significantly greater central retinal thickness.

Studies of pegaptanib, a pegylated aptamer against the VEGF-A 165 isomer, have similarly demonstrated promising results for patients with diabetic macular edema. Sultan et al. randomized 260 patients with macular edema to receive pegaptanib or sham injections every 6 weeks, with photoocoagulation delivered as required after 18 weeks [146]. Over the 2-year follow-up, patients treated with pegaptanib recorded an average of one-line gain in visual acuity compared with controls, with significantly fewer laser treatments required.

Despite the promising clinical benefits of anti-VEGF agents, uncertainty into long-term potential side effects including infection, retinal detachment, vitreous hemorrhage and systemic ischemic events remains. Therefore, given the absence of long-term safety data in patients with DM, evaluating the risks and benefits for the individual patient is advised.

The role of anti-VEGF medications was discussed by the NHMRC, AAO, Malaysian and SIGN with varying detail on indications and timing. Given the emerging evidence at the time of their publications, the SIGN and AAO guidelines simply acknowledged that anti-VEGF medications were useful as an adjunct to laser for the treatment of PDR and macular edema. The Malaysian guideline indicated that intraocular anti-VEGF agents were to be considered in addition to intraocular steroids and vitrectomy in the management of advanced retinopathy. The most comprehensive recommendation was from the NHMRC that recommended anti-VEGF for consideration in use as an adjunct to laser treatment and prior to vitrectomy. The authors also acknowledged the accumulating evidence for its role in reducing macular thickness and for consideration in diabetic macular edema.

Recommendations for the use of intraocular corticosteroids in treatment of DME achieved consensus across the guidelines. In general, the NHMRC, AAO, SIGN and Malaysian guidelines all acknowledged that intravitreal corticosteroids including triamcinolone (IVTA) was widely used in managing DME that was refractory to focal/grid laser. The NHMRC further recommended that IVTA alone could also be considered as adjunct to PRP for proliferative DR, or for treating large hard exudates. However, guidelines were also reserved in their recommendations, by acknowledging potential adverse effects and unresolved issues such as optimal dosage, timing and duration of therapy. The recommendations were consistent with the current literature. The multicenter randomized control trial conducted by the DRCR.net failed to demonstrate benefit in visual acuity at 3 years in eyes with DME that were treated with IVTA compared with focal/grid photoocoagulation [147]. Comparatively, Gillies et al., in a smaller placebo-controlled trial of patients with macular edema refractory to prior laser, demonstrated that IVTA alone improved visual acuity in 56% of patients compared with 26% (placebo injection) [148]. This effect persisted after 2 years. However, in both studies, IVTA was associated with adverse events including ocular hypertension and early cataract formation. Thus, current evidence supports the use of IVTA in patients with refractory DME. However, the individualized treatment considering the risk of adverse outcomes is imperative.

**Expert commentary**

The preparation of evidence-based guidelines is highlighted by the WHO as an important component in the concerted effort to eliminate avoidable blindness [149]. This review has highlighted considerable regional variation in recommendations between guidelines, despite the availability of common medical evidence. Consensus among guidelines was achieved overall regarding the need for optimization of the established risk factors, timing of initial screening and indications for laser photoocoagulation and vitrectomy.

Differences between guidelines have been addressed by a growing body of evidence. Ethnic background is emerging as an important risk factor. As such, south Asian and Pacific Island populations should now be considered ‘high-risk’ populations. Current evidence supports all patients with Type 2 DM commence screening at the time of diagnosis. Patients with Type 1 DM require examination at puberty. Women with DM should be examined before pregnancy, and during their first trimester. Patients with DM, regardless of the severity of DR, should be examined at least every 2 years. The detection of referable retinopathy in accordance with the international scoring system can be reliably made with a single, 45°, non-mydriatic camera, using
a trained operator, with off-site grading by an ophthalmologist. In areas where this is not possible, an ophthalmologist or trained ophthalmic medical officer or optometrist can be used to perform retinal examination through a dilated pupil.

Worldwide, DM and DR is escalating, particularly in low and low-middle income countries [30]. However, this review demonstrated that of the comprehensive DR guidelines available, a minority were developed from low-resource regions. This is pertinent, given that none of the guidelines reviewed addressed the feasibility of implementing recommendations. In order to plan DR services in these ‘high-risk’ regions, key themes have emerged from Latin America, south India and rural China. These have prioritized the need to obtain accurate epidemiologic data, patient identification, retinal examination methods that take into account available resources, establishing centers for photocoagulation, education for the whole population and need for integration into a public health system [150–152].

**Five-year view**
The prevalence of blindness caused by DR will escalate in developing nations over the next 5 years. Governments of low-resourced countries who have prioritized DR in their national blindness prevention plans will implement national DR screening programs of varying descriptions. Survey methodology such as the adopted Rapid Assessment of Avoidable Blindness will provide estimates of DR prevalence and guide the distribution of resources to manage DR. However, given that DM has a younger age of onset in developing countries, higher quality epidemiologic studies will be required to capture an accurate representation of disease distribution. Successful DR management programs will need to integrate evidence-based planning in order to maximize efficiency of healthcare resources. The development of lower-cost retinal cameras and lasers will make it more accessible for patients to receive treatment. Educating and empowering primary eye care workers with basic skills has been demonstrated as a feasible intervention in low-resource environments and will ensure that timely diagnosis and highest quality of care is instituted to the greatest number and at all levels of society. The greatest challenge to the sustainability of DR management programs will be to ensure that patients are adequately followed-up and are compliant with treatment. This will require emphasis on public education by community leaders and healthcare workers in order to improve knowledge and awareness of DM and its consequences.

**Key issues**
- Diabetic retinopathy (DR) is an important contributor to the burden of vision impairment.
- DR management needs to be guided by evidence-based recommendations on who should be examined, methods for retinal examination, frequency of review, where to refer and interventions for treatment.
- A simple classification system with clear referral criteria must be disseminated at all levels of the health system in order to minimize inappropriate referrals.
- Non-mydriatic single 45° field retinal photography has adequate sensitivity, specificity and low technical failure rate to detect DR. It is a cost-effective option.
- Adults with diabetes need to have visual acuity assessment with either dilated retinal examination or retinal imaging at time of diagnosis of diabetes.
- Patients with diabetes without evidence of DR can be safely examined every 2 years. Patients at high risk (long duration of diabetes, poor glycemic and lipid control and hypertension) require annual examination.
- In addition to ophthalmologists, low-resourced countries must train and employ healthcare workers to conduct DR screening in order to bridge the gap between growing demand and supply of competent workforce.
- DR guidelines must be integrated into the existing public health system to achieve sustainability.

**References**
- Papers of special note have been highlighted as:
  - of interest
  - of considerable interest

• Original paper that compared the prevalence of diabetes from around the world according to socioeconomic status. Offered insight into the difference in the demography of patients with diabetes in developing versus developed countries, and projections into the future.


Excellent recent pooled analysis of epidemiological studies documenting the longitudinal profile of risk factors for diabetic retinopathy. Incorporates recent data from Southeast Asia and the Pacific Islands.


39 Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic
Chakrabarti, Harper & Keefe


Diabetic retinopathy management guidelines

Review

82 The Liverpool Diabetic Eye Study provided insight into modalities and optimal screening interval for patients with diabetes through a well-conducted longitudinal cohort study design. The results gave insight into the natural progression of diabetic retinopathy and implications for screening intervals.
85 Insightful systematic review of health-economic evidence for screening for diabetic retinopathy and alternate modalities. This paper is highly relevant for planning diabetic retinopathy services in low-resourced environments.


ETDRS Report Number 7. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics.
Diabetic retinopathy management guidelines


### Appendix A. Table of excluded guidelines published in English.

<table>
<thead>
<tr>
<th>Publisher</th>
<th>Title</th>
<th>Country</th>
<th>Date of publication</th>
<th>Intended audience</th>
<th>Epidemiology</th>
<th>Stages of DR</th>
<th>Detection</th>
<th>Management</th>
<th>Evidence-based recommendation</th>
<th>Comment</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Zealand Ministry of Health</td>
<td>National Diabetes Retinal Screening Grading System and Referral Guidelines</td>
<td>New Zealand</td>
<td>2008</td>
<td>Ophthalmic specialists and health services coordinators</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Content included in the Pacific Eye Institute Guideline (2010)</td>
<td></td>
</tr>
<tr>
<td>American Optometric Association</td>
<td>Optometric Clinical Practice Guideline. Care of the Patient with Diabetes Mellitus</td>
<td>USA</td>
<td>2009</td>
<td>Optometrists</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Recommendations based upon AAO publication (2008)</td>
<td>[2]</td>
</tr>
<tr>
<td>ADA</td>
<td>Screening for Diabetic Retinopathy</td>
<td>USA</td>
<td>2002</td>
<td>Clinical practitioners</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Contributed to AAO publication (2008)</td>
<td>[3]</td>
</tr>
<tr>
<td>ADS</td>
<td>National Evidence-Based Clinical Care Guidelines for Type 1 Diabetes in Children, Adolescents and Adults</td>
<td>Australia</td>
<td>2011</td>
<td>Clinical practitioners</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Did not discuss all key components. Epidemiology and detection recommendations discussed</td>
<td>[4]</td>
</tr>
<tr>
<td>ICO</td>
<td>Diabetic Retinopathy Management Recommendations</td>
<td>USA</td>
<td>2011</td>
<td>Ophthalmic specialists</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Recommendations based upon AAO publication (2008)</td>
<td>[5]</td>
</tr>
</tbody>
</table>

## Appendix A. Table of excluded guidelines published in English (cont.).

<table>
<thead>
<tr>
<th>Publisher</th>
<th>Title</th>
<th>Country</th>
<th>Date of publication</th>
<th>Intended audience</th>
<th>Epidemiology</th>
<th>Stages of DR</th>
<th>Detection</th>
<th>Management</th>
<th>Evidence-based recommendation</th>
<th>Comment</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCO</td>
<td>Diabetic Retinopathy Screening and Ophthalmology Clinic Set Up in England</td>
<td>UK</td>
<td>2010</td>
<td>Health services coordinators</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Not a clinical management guideline</td>
<td>[6]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Useful for health services planning</td>
<td></td>
</tr>
<tr>
<td>HTBS</td>
<td>Organisation of Services for Diabetic Retinopathy Screening</td>
<td>Scotland</td>
<td>2002</td>
<td>Clinical practitioners</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Did not discuss all key components</td>
<td>[7]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Grading and detection recommendations discussed</td>
<td></td>
</tr>
<tr>
<td>Ministry of Public Health and Sanitation</td>
<td>Retinopathy in: National Clinical Guidelines for Management of Diabetes Mellitus</td>
<td>Kenya</td>
<td>2010</td>
<td>Clinical practitioners, health services coordinators and primary eye care workers</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Did not discuss all key components</td>
<td>[8]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Detection recommendations discussed</td>
<td></td>
</tr>
<tr>
<td>IDF</td>
<td>Eye Damage in: Global Guideline for Type 2 Diabetes</td>
<td>Belgium</td>
<td>2005</td>
<td>Clinical practitioners, health services coordinators and primary eye care workers</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Did not discuss all key components</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Detection and management recommendations discussed</td>
<td></td>
</tr>
</tbody>
</table>

### Appendix B. Table of published guidelines not in English.

<table>
<thead>
<tr>
<th>Publisher</th>
<th>Title</th>
<th>Country</th>
<th>Date of publication</th>
<th>Language of publication</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Norway College of General Practitioners</td>
<td>Diabetic Retinopathy Screening in: Guidelines for Diabetes in General Practice</td>
<td>Norway</td>
<td>2000</td>
<td>Norwegian</td>
<td>[10]</td>
</tr>
<tr>
<td>Medica del Instituto Mexicano del Seguro</td>
<td>Diagnosis and Treatment of Diabetic Retinopathy</td>
<td>Mexico</td>
<td>2011</td>
<td>Spanish</td>
<td>[12]</td>
</tr>
<tr>
<td>Slovene Medical Society</td>
<td>Guidelines for Screening and Treatment for Diabetic Retinopathy</td>
<td>Slovenia</td>
<td>2010</td>
<td>Slovene</td>
<td>[13]</td>
</tr>
<tr>
<td>Tagaki H</td>
<td>Guideline-Based Planning for the Treatment of Diabetic Retinopathy</td>
<td>Japan</td>
<td>2010</td>
<td>Japanese</td>
<td>[14]</td>
</tr>
<tr>
<td>Professional Association of Ophthalmologists in Germany</td>
<td>Treatment of Diabetic Maculopathy</td>
<td>Germany</td>
<td>2011</td>
<td>German</td>
<td>[15]</td>
</tr>
<tr>
<td>Polak et al.</td>
<td>Revised Guideline for Diabetic Retinopathy: Screening, Diagnosis and Treatment</td>
<td>The Netherlands</td>
<td>2008</td>
<td>Dutch</td>
<td>[16]</td>
</tr>
<tr>
<td>Deb et al.</td>
<td>Screening for Diabetic Retinopathy in France</td>
<td>France</td>
<td>2004</td>
<td>French</td>
<td>[17]</td>
</tr>
<tr>
<td>IAPB Latin America</td>
<td>Clinical Practice Guidelines. Diabetic Retinopathy – Latin America</td>
<td>Ecuador</td>
<td>2011</td>
<td>Spanish</td>
<td>[18]</td>
</tr>
<tr>
<td>Kalvodová</td>
<td>Screening for Diabetic Retinopathy in the Czech Republic Guideline</td>
<td>Czech Republic</td>
<td>2002</td>
<td>Czech</td>
<td>[19]</td>
</tr>
</tbody>
</table>

IAPB: International Agency for Prevention of Blindness; SERV: Spanish Retina and Vitreous Society.
### Appendix C. Comparison of different diabetic retinopathy classification systems.

<table>
<thead>
<tr>
<th>ETDRS level</th>
<th>International Classification (AAO, NHMRC, WHO, Pacific Eye Institute, New Zealand, Malaysia, Aravind, South Africa)</th>
<th>National Screening Committee (UK)</th>
<th>SDRGS (Scotland)</th>
<th>RCO (UK)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 – none</td>
<td>No apparent retinopathy</td>
<td>R0 – none</td>
<td>R0 – none</td>
<td>None</td>
</tr>
<tr>
<td>20 – microaneurysms only</td>
<td>Mild NPDR</td>
<td>R1 – background retinopathy</td>
<td>R1 – mild background DR (BDR)</td>
<td>Low Risk</td>
</tr>
<tr>
<td>35 – mild NPDR</td>
<td>Moderate NPDR</td>
<td>R2 – preproliferative retinopathy</td>
<td>R2 – moderate BDR</td>
<td>High risk</td>
</tr>
<tr>
<td>43 – moderate NPDR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>47 – moderate severe NPDR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>53 A – severe NPDR</td>
<td>Severe NPDR</td>
<td>R3 – Severe BDR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>53 E – very severe NPDR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>61 – PDR</td>
<td>PDR</td>
<td>R3 – proliferative retinopathy</td>
<td>R4 – PDR</td>
<td>PDR</td>
</tr>
<tr>
<td>65 – moderate PDR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>71, 75 – high-risk PDR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>81, 85 – advanced PDR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**References**